Tonix Pharmaceuticals Holding Corp.（以下简称Tonix制药）宣布，其研发的TNX-1900（强效鼻内催产素）在一项由研究者发起的一期药效学研究中，已完成首例受试者给药。该研究旨在评估TNX-1900在治疗偏头痛及颅面疼痛方面的潜在疗效。
TNX-1900作为一种鼻内给药的强化催产素制剂，其独特的作用机制可能为疼痛管理领域带来新的突破。此次一期研究将重点探索药物的安全性与耐受性，同时通过药效学指标分析其对神经系统的影响。
若研究结果积极，TNX-1900有望为全球数百万受慢性疼痛困扰的患者提供创新治疗方案。公司表示将密切跟进研究进展，并及时向科学界与公众披露关键数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.